JP2013537229A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013537229A5 JP2013537229A5 JP2013529256A JP2013529256A JP2013537229A5 JP 2013537229 A5 JP2013537229 A5 JP 2013537229A5 JP 2013529256 A JP2013529256 A JP 2013529256A JP 2013529256 A JP2013529256 A JP 2013529256A JP 2013537229 A5 JP2013537229 A5 JP 2013537229A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- indol
- triazole
- mercapto
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38240010P | 2010-09-13 | 2010-09-13 | |
| US61/382,400 | 2010-09-13 | ||
| PCT/US2011/037285 WO2011146803A1 (en) | 2010-05-20 | 2011-05-20 | Method of treating lung adenocarcinoma with hsp90 inhibitory compounds |
| USPCT/US2011/037285 | 2011-05-20 | ||
| PCT/US2011/051320 WO2012037072A1 (en) | 2010-09-13 | 2011-09-13 | Hsp90 inhibitors for treating non-small cell lung cancers in wild-type egfr and/or kras patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013537229A JP2013537229A (ja) | 2013-09-30 |
| JP2013537229A5 true JP2013537229A5 (enExample) | 2014-11-06 |
Family
ID=44674905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013529256A Pending JP2013537229A (ja) | 2010-09-13 | 2011-09-13 | 野生型ｅｇｆｒ及び／又はｋｒａｓ患者において非小細胞肺癌を処置するためのｈｓｐ９０阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120064175A1 (enExample) |
| EP (1) | EP2616063A1 (enExample) |
| JP (1) | JP2013537229A (enExample) |
| CN (1) | CN103269701A (enExample) |
| AU (1) | AU2011302344B2 (enExample) |
| CA (1) | CA2810254A1 (enExample) |
| WO (1) | WO2012037072A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1934185A1 (en) | 2005-08-12 | 2008-06-25 | Synta Pharmaceuticals Corporation | Pyrazole compounds that modulate hsp90 activity |
| US20070250391A1 (en) * | 2006-04-05 | 2007-10-25 | Prade Hendrik D | Merchandising system and method for food and non-food items for a meal kit |
| US8034834B2 (en) | 2006-05-25 | 2011-10-11 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders with HSP90 inhibitors |
| CA2653336C (en) | 2006-05-25 | 2014-10-28 | Synta Pharmaceuticals Corp. | Method for treating non-hodgkin's lymphoma |
| AU2007267859B2 (en) | 2006-05-25 | 2012-04-12 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate Hsp90 activity |
| EP2034996A2 (en) | 2006-05-25 | 2009-03-18 | Synta Pharmaceuticals Corporation | Triazole compounds that modulate hsp90 activity |
| US9156836B2 (en) * | 2008-05-16 | 2015-10-13 | Synta Pharmaceuticals Corp. | Tricyclic triazole compounds that modulate HSP90 activity |
| US8450500B2 (en) | 2008-06-04 | 2013-05-28 | Synta Pharmaceuticals Corp. | Pyrrole compounds that modulate HSP90 activity |
| WO2009158026A1 (en) | 2008-06-27 | 2009-12-30 | Synta Pharmaceuticals Corp. | Hydrazonamide compounds that modulate hsp90 activity |
| WO2010017479A1 (en) * | 2008-08-08 | 2010-02-11 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| WO2010017545A2 (en) | 2008-08-08 | 2010-02-11 | Synta Pharamceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| US20130045992A1 (en) | 2010-01-28 | 2013-02-21 | President And Fellows Of Harvard College | Compositions and Methods for Enhancing Proteasome Activity |
| WO2011133520A1 (en) | 2010-04-19 | 2011-10-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
| WO2012154967A1 (en) | 2011-05-12 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Proteostasis regulators |
| WO2013006864A2 (en) | 2011-07-07 | 2013-01-10 | Synta Pharmaceuticals Corp. | Treating cancer with hsp90 inhibitory compounds |
| WO2013067165A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
| JP2014532712A (ja) | 2011-11-02 | 2014-12-08 | シンタ ファーマシューティカルズ コーポレーション | トポイソメラーゼｉ阻害剤とｈｓｐ９０阻害剤の組合せを使用する癌療法 |
| WO2013074594A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
| JP2015516439A (ja) * | 2012-05-10 | 2015-06-11 | シンタ ファーマシューティカルズ コーポレーション | Ｈｓｐ９０阻害化合物で癌を治療すること |
| WO2013170182A1 (en) * | 2012-05-11 | 2013-11-14 | Synta Pharmaceuticals Corp. | Treating cancer with an hsp90 inhibitory compound |
| EP2849853A1 (en) * | 2012-05-16 | 2015-03-25 | Synta Pharmaceuticals Corp. | Pre-selection of subjects for therapeutic treatment with an hsp90 inhibitor based on hypoxic status |
| US9849135B2 (en) | 2013-01-25 | 2017-12-26 | President And Fellows Of Harvard College | USP14 inhibitors for treating or preventing viral infections |
| WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| KR20160015076A (ko) | 2014-07-30 | 2016-02-12 | 삼성전자주식회사 | c-Met 저해제의 효능 예측을 위한 바이오마커 Hsp90 |
| KR102259232B1 (ko) | 2014-08-25 | 2021-05-31 | 삼성전자주식회사 | 항 c-Met/항 Ang2 이중 특이 항체 |
| MX2018013863A (es) * | 2016-05-18 | 2019-08-12 | Esanex Inc | Terapias combinadas que usan derivados de indazolilbenzamida para el tratamiento del cancer. |
| EP3653611A1 (en) * | 2018-11-15 | 2020-05-20 | Centre National De La Recherche Scientifique | Inhibitors of metallo-beta-lactamases |
| CN110105368B (zh) * | 2019-05-09 | 2022-01-07 | 上海大学 | 去氧紫杉烷类似物及其制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| ES2564127T5 (es) * | 2004-06-04 | 2020-03-26 | Genentech Inc | Mutaciones en EGFR |
| RS52642B (sr) | 2004-11-18 | 2013-06-28 | Synta Pharmaceuticals Corp. | Jedinjenja triazola koja modulišu aktivnost hsp90 |
| US8034834B2 (en) * | 2006-05-25 | 2011-10-11 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders with HSP90 inhibitors |
| KR20100057030A (ko) * | 2007-08-13 | 2010-05-28 | 신타 파마슈티칼스 코프. | Ｈｓｐ90의 활성을 조절하는 트라이아졸 화합물 |
| ES2331041B1 (es) | 2008-03-11 | 2010-10-01 | Fco. Javier Gil Vizuete | Dispositivo para la extraccion de personas en emergencia vital y procedimiento de utilizacion. |
| US20090232906A1 (en) * | 2008-03-14 | 2009-09-17 | Bionumerik Pharmaceuticals, Inc. | Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions |
| NZ599445A (en) * | 2009-10-19 | 2014-04-30 | Synta Pharmaceuticals Corp | Combination cancer therapy with hsp90 inhibitory compounds |
| WO2011133520A1 (en) * | 2010-04-19 | 2011-10-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
| EP2560641A2 (en) * | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor |
-
2011
- 2011-09-13 AU AU2011302344A patent/AU2011302344B2/en not_active Ceased
- 2011-09-13 CA CA2810254A patent/CA2810254A1/en not_active Abandoned
- 2011-09-13 WO PCT/US2011/051320 patent/WO2012037072A1/en not_active Ceased
- 2011-09-13 EP EP11760643.4A patent/EP2616063A1/en not_active Withdrawn
- 2011-09-13 JP JP2013529256A patent/JP2013537229A/ja active Pending
- 2011-09-13 CN CN2011800437944A patent/CN103269701A/zh active Pending
- 2011-09-13 US US13/231,183 patent/US20120064175A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013537229A5 (enExample) | ||
| JP2014507443A5 (enExample) | ||
| JP2014533299A5 (enExample) | ||
| JP2013508378A5 (enExample) | ||
| AU2011302344B2 (en) | HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients | |
| US10500193B2 (en) | Combination therapy of HSP90 inhibitors with platinum-containing agents | |
| JP2009534386A5 (enExample) | ||
| US20130171105A1 (en) | Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor | |
| JP2015518008A5 (enExample) | ||
| CA2853799A1 (en) | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors | |
| US20130331357A1 (en) | Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors | |
| HRP20140704T1 (hr) | Spojevi triazola koji moduliraju hsp90 aktivnost | |
| JP2015516439A (ja) | Ｈｓｐ９０阻害化合物で癌を治療すること | |
| JP2019529518A5 (enExample) | ||
| NZ599445A (en) | Combination cancer therapy with hsp90 inhibitory compounds | |
| CA2854188A1 (en) | Combination therapy of hsp90 inhibitors with braf inhibitors | |
| JP2014520808A (ja) | Ｈｓｐ９０阻害化合物を用いた癌の治療 | |
| JP2011006480A5 (enExample) | ||
| JP2012532100A5 (enExample) | ||
| JP2012505871A5 (enExample) | ||
| PT2328893E (pt) | Compostos de triazol que modulam a actividade da hsp90 | |
| JP2012526148A5 (enExample) | ||
| JP2020527173A5 (enExample) | ||
| JP2017529389A5 (enExample) | ||
| JP2010524937A5 (enExample) |